Shots:
- Ikarovec has entered into an exclusive worldwide option agreement for VectorBuilder’s AAV capsid technology to be used with Ikarovec’s IKAR-003 for intermediate age-related macular degeneration (AMD)
- As per the deal, following successful tech evaluation, Ikarovec will lead the clinical development & commercialization of IKAR-003, with the proposed transaction for its intermediate AMD potential expected to exceed $1B
- VectorBuilder’s capsid tech enables office-based intravitreal delivery of IKAR-003, expanding access for intermediate AMD pts, with a one-time AAV gene therapy combining neuroprotection & complement modulation to prevent disease progression & preserve vision
Ref: Businesswire | Image: Ikarovec & VectorBuilder | Press Release
Related News: Insilico Medicine and Servier Enter ~$888M R&D Alliance to Advance Novel Oncology Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
